Results 81 to 90 of about 5,080 (193)

Brain pathology in relation to somatic diseases: Exploring the body–brain crosstalk

Journal of Internal Medicine, Volume 300, Issue 3, Page 223-237, September 2026.
Abstract Several somatic diseases have been consistently linked with an increased dementia risk. However, the underlying neuropathological substrates remain poorly characterized. This narrative review aims to summarize evidence on the association between common age‐related somatic conditions (i.e., heart diseases, type 2 diabetes, kidney disease, liver
G. Grande, M. Valletta, F. Gasparini, D. L. Vetrano, M. Canevelli, J. R. Bacci, C. Qiu, A. Marengoni, M. Toccaceli Blasi, H. Xu, L. Fratiglioni, M. M. Mielke   +11 more
wiley   +1 more source

Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

The Journal of Prevention of Alzheimer's Disease
Background: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial.
Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich   +13 more
doaj   +1 more source

Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease

INNOVATIONS in Pharmacy
The Food and Drug Administration granted traditional approval of lecanemab for the treatment of Alzheimer’s disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets
Connie Yoon, Corey Groff, Olivia Criss
doaj   +1 more source

Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data

Alzheimer’s Research & Therapy
Background Lecanemab was recently approved for the treatment of patients with early Alzheimer’s disease (AD) and demonstrated reduced senile amyloid plaque and less decline on the measures of cognition and function in clinical trials.
Moeko Noguchi-Shinohara, Takahiro Yoshinobu, Taro Ozaki, Daiki Muramatsu, Ayano Shima, Yasuhiro Sakashita, Yasutake Tada, Hiroki Yamaguchi, Junji Komatsu, Tokuhei Ikeda, Kenjiro Ono   +10 more
doaj   +1 more source

Lecanemab Treatment in a Specialty Memory Clinic

JAMA Neurology
ImportanceTwo monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most significant adverse events associated with these therapies are infusion-related reactions and amyloid-related imaging ...
Paczynski, Madeline, Hofmann, Anna, Posey, Zachary, Gregersen, Maren, Rudman, Michelle, Ellington, Dawn, Aldinger, Melissa, Musiek, Erik S., Holtzman, David M., Bateman, Randall J., Long, Justin M., Ghoshal, Nupur, Carr, David B., Dow, Alan, Namazie-Kummer, Sheyda, Jana, Nayid, Xiong, Chengjie, Morris, John C., Benzinger, Tammie L. S., Schindler, Suzanne E., Snider, B. Joy   +20 more
openaire   +2 more sources

The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia

Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector ...
De Strooper, Bart, Xu, Ciana, Poovathingal, Suresh, Wolfs, Leen, Albertini, Giulia, Dewilde, Maarten, van Lieshout, Veerle, Jaspers, Tom, Snellinx, An, Cuypers, Marie-Lynn, Pasciuto, Emanuela, Fiers, Mark, Wojno, Marta, Serneels, Lurgarde, Craessaerts, Katleen, Horre, Katrien, Zielonka, Magdalena, Davie, Kristofer   +17 more
core   +3 more sources

Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report

Journal of Alzheimer's Disease Reports
Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic events during extended ...
Yugo Takahashi, Naoyuki Shiraishi, Akihiro Tsukahara, Yukari Matsuda, Takuya Nishina, Hiroo Yoshikawa, Takashi Uzu, Etsuro Mori   +7 more
doaj   +1 more source

Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

Alzheimer’s Research & Therapy
Background The safety data of lecanemab in the post-marketing period has yet to be fully investigated in the current literature. We aimed to identify and characterise the safety profile of lecanemab in the post-marketing period.
Xiaoxuan Xing, Xiaotong Zhang, Ke Wang, Zhizhou Wang, Yingnan Feng, Xiaoxi Li, Yiming Hua, Lan Zhang, Xianzhe Dong   +8 more
doaj   +1 more source

Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations

Alzheimer's & Dementia
Abstract Background A subcutaneous formulation of the anti‐amyloid antibody lecanemab is being developed to improve patient convenience and safety. Herein, we will give an update on the early development history of subcutaneous lecanemab, including establishing the bioavailability and ...
Penner, Natasha, Rawal, Sumit, Aluri, Jagadeesh, Li, David, Reyderman, Larisa, Hersch, Steven, Dhadda, Shobha, Irizarry, Michael C., Kramer, Lynn D   +8 more
openaire   +2 more sources

Proposing a Coverage With Evidence Development Framework for Accelerated Approval at the U.S. Food and Drug Administration

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
Dhanush Bearelly, Purav Desai, David T. Zhu, Rajesh Balkrishnan   +3 more
wiley   +1 more source